EJCB:抑制乳腺癌肿瘤细胞关键因子的揭示

2015-02-10 MedSci MedSci原创

一项由纽约爱因斯坦医学院的西班牙研究员何塞哈维尔•布拉沃 - 科尔德罗领导的新研究中,详细介绍了低表达前纤维蛋白-1的细胞如何在乳腺癌的肿瘤细胞中增加其转移并侵入其他组织的能力。 近年来,医学专家一直对开发新的治疗方法来对抗癌细胞的扩散非常感兴趣,癌细胞扩散也是癌症患者的最大的死亡原因。 然而,抑制或防止肿瘤细胞从原发肿瘤扩散的有效的治疗方法还没有被开发,其中关键一步就是肿瘤在转移过程中达到不

一项由纽约爱因斯坦医学院的西班牙研究员何塞哈维尔•布拉沃 - 科尔德罗领导的新研究中,详细介绍了低表达前纤维蛋白-1的细胞如何在乳腺癌的肿瘤细胞中增加其转移并侵入其他组织的能力。

近年来,医学专家一直对开发新的治疗方法来对抗癌细胞的扩散非常感兴趣,癌细胞扩散也是癌症患者的最大的死亡原因。

然而,抑制或防止肿瘤细胞从原发肿瘤扩散的有效的治疗方法还没有被开发,其中关键一步就是肿瘤在转移过程中达到不同的器官。

现在,由纽约艾伯特爱因斯坦医学院的一位西班牙研究员何塞哈维尔•布拉沃—科尔德罗领导领导的一项新研究发表在《欧洲细胞生物学》杂志上,并揭示了前纤维蛋白-1如何对肿瘤侵袭过程中形成确定结构进行干预。

布拉沃—科尔德罗解释说:“为了达到这种有效程度,这些肿瘤细胞形成了一个称作侵袭伪足的亚细胞结构(从from the Latin invado, invade, and podio, feet; invasive feet),癌细胞借此来向机体的其他部分扩散。”

利用高分辨率显微镜技术,研究者研究了缺乏前纤维蛋白-1的肿瘤细胞的侵袭伪足的动力学,并描述了它们的作用和调节途径。

因此当乳腺癌肿瘤患者体内前纤维蛋白-1表达水平的下降和人乳腺癌肿瘤扩散到其他器官能力的增强息息相关。

这位西班牙的科学家描述说:“奇怪的是,与对照组细胞相比,缺乏前纤维蛋白-1的细胞显示的极强侵袭能力是通过侵袭伪足介导的。这就像我们已经采取了关闭制动系统,却失去对车辆的控制。”

更重要的是,布拉沃-科尔德罗补充说:“在前纤维蛋白-1不存在情况下,当细胞外基质降解时,侵袭伪足则表现为更为积极,并具有很强的侵入性的结构,这也解释了这些细胞的高转移潜能。”

一个关键结构

这项工作是与来自匹兹堡大学(宾夕法尼亚,美国)的研究人员合作完成的,研究表明了树突状伪足的内部结构和肌动蛋白细胞骨架(主要是真核细胞的脚手架)在它们的功能上的重要性,以及前纤维蛋白-1如何在调控中起着至关重要的作用。

专家指出:“如果我们破坏了脚手架,该结构就不能形成;如果我们以同样的方式有效的完成脚手架的组装,我们就可以形成具有更强侵袭力的组织。我们应该应用这些变量来抑制肿瘤的侵袭,让前纤维蛋白-1来调节这种平衡。”

研究者还描述了缺乏前纤维蛋白-1的细胞中能够让侵袭伪足有更强侵袭能力的分子途径。这个分子机制有效的在他们的成熟过程中起到了重要作用。

这项研究的主要作者、索诺拉州大学(墨西哥)亚历杭德拉•巴伦苏埃拉 - 伊格莱西亚斯声明:“这是一个成熟的问题。在缺乏这种蛋白质时侵袭伪足成熟更快,通过抑制前纤维蛋白-1的表达来迅速降解基质,因此,这些细胞具有更强的侵袭能力。”

目前研究人员强调:“所有的侵袭机制都是发现在亚细胞水平,我们确定了‘螺母和螺栓’的关系。我们必须调整以防止肿瘤细胞扩散。这将大大有助于开发抑制肿瘤转移过程的新治疗方法。”他们得出结论。

原始出处

A. Valenzuela-Iglesias, V.P. Sharma, B.T. Beaty, Z. Ding, L.E. Gutierrez-Millan, P. Roy, J.S. Condeelis, J.J. Bravo-Cordero. Profilin1 regulates invadopodium maturation in human breast cancer cells. European Journal of Cell Biology, 2014;

本文是MedSci编译,欢迎转载,转载请注明出处,非常感谢!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1942612, encodeId=8d27194261283, content=<a href='/topic/show?id=b433301696d' target=_blank style='color:#2F92EE;'>#关键因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30169, encryptionId=b433301696d, topicName=关键因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Tue Oct 20 20:13:00 CST 2015, time=2015-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16605, encodeId=7de9166050c, content=非常好的文章,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Fri Feb 20 15:43:00 CST 2015, time=2015-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16594, encodeId=50d41659463, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Fri Feb 20 09:21:00 CST 2015, time=2015-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15778, encodeId=9e8115e786d, content=以阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:03:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312905, encodeId=6d231312905ed, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Thu Feb 12 07:13:00 CST 2015, time=2015-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15329, encodeId=9a8e1532974, content=Profilin1 主要调节invadopodium成熟,与乳腺癌侵犯有关, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=114.90.43.**, createdTime=Tue Feb 10 19:28:00 CST 2015, time=2015-02-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1942612, encodeId=8d27194261283, content=<a href='/topic/show?id=b433301696d' target=_blank style='color:#2F92EE;'>#关键因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30169, encryptionId=b433301696d, topicName=关键因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Tue Oct 20 20:13:00 CST 2015, time=2015-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16605, encodeId=7de9166050c, content=非常好的文章,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Fri Feb 20 15:43:00 CST 2015, time=2015-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16594, encodeId=50d41659463, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Fri Feb 20 09:21:00 CST 2015, time=2015-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15778, encodeId=9e8115e786d, content=以阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:03:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312905, encodeId=6d231312905ed, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Thu Feb 12 07:13:00 CST 2015, time=2015-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15329, encodeId=9a8e1532974, content=Profilin1 主要调节invadopodium成熟,与乳腺癌侵犯有关, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=114.90.43.**, createdTime=Tue Feb 10 19:28:00 CST 2015, time=2015-02-10, status=1, ipAttribution=)]
    2015-02-20 orthoW

    非常好的文章,学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1942612, encodeId=8d27194261283, content=<a href='/topic/show?id=b433301696d' target=_blank style='color:#2F92EE;'>#关键因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30169, encryptionId=b433301696d, topicName=关键因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Tue Oct 20 20:13:00 CST 2015, time=2015-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16605, encodeId=7de9166050c, content=非常好的文章,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Fri Feb 20 15:43:00 CST 2015, time=2015-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16594, encodeId=50d41659463, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Fri Feb 20 09:21:00 CST 2015, time=2015-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15778, encodeId=9e8115e786d, content=以阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:03:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312905, encodeId=6d231312905ed, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Thu Feb 12 07:13:00 CST 2015, time=2015-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15329, encodeId=9a8e1532974, content=Profilin1 主要调节invadopodium成熟,与乳腺癌侵犯有关, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=114.90.43.**, createdTime=Tue Feb 10 19:28:00 CST 2015, time=2015-02-10, status=1, ipAttribution=)]
    2015-02-20 orthoW

    很不错学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1942612, encodeId=8d27194261283, content=<a href='/topic/show?id=b433301696d' target=_blank style='color:#2F92EE;'>#关键因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30169, encryptionId=b433301696d, topicName=关键因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Tue Oct 20 20:13:00 CST 2015, time=2015-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16605, encodeId=7de9166050c, content=非常好的文章,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Fri Feb 20 15:43:00 CST 2015, time=2015-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16594, encodeId=50d41659463, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Fri Feb 20 09:21:00 CST 2015, time=2015-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15778, encodeId=9e8115e786d, content=以阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:03:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312905, encodeId=6d231312905ed, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Thu Feb 12 07:13:00 CST 2015, time=2015-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15329, encodeId=9a8e1532974, content=Profilin1 主要调节invadopodium成熟,与乳腺癌侵犯有关, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=114.90.43.**, createdTime=Tue Feb 10 19:28:00 CST 2015, time=2015-02-10, status=1, ipAttribution=)]
    2015-02-16 windmilL1989

    以阅

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1942612, encodeId=8d27194261283, content=<a href='/topic/show?id=b433301696d' target=_blank style='color:#2F92EE;'>#关键因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30169, encryptionId=b433301696d, topicName=关键因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Tue Oct 20 20:13:00 CST 2015, time=2015-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16605, encodeId=7de9166050c, content=非常好的文章,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Fri Feb 20 15:43:00 CST 2015, time=2015-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16594, encodeId=50d41659463, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Fri Feb 20 09:21:00 CST 2015, time=2015-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15778, encodeId=9e8115e786d, content=以阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:03:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312905, encodeId=6d231312905ed, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Thu Feb 12 07:13:00 CST 2015, time=2015-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15329, encodeId=9a8e1532974, content=Profilin1 主要调节invadopodium成熟,与乳腺癌侵犯有关, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=114.90.43.**, createdTime=Tue Feb 10 19:28:00 CST 2015, time=2015-02-10, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1942612, encodeId=8d27194261283, content=<a href='/topic/show?id=b433301696d' target=_blank style='color:#2F92EE;'>#关键因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30169, encryptionId=b433301696d, topicName=关键因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Tue Oct 20 20:13:00 CST 2015, time=2015-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16605, encodeId=7de9166050c, content=非常好的文章,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Fri Feb 20 15:43:00 CST 2015, time=2015-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16594, encodeId=50d41659463, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Fri Feb 20 09:21:00 CST 2015, time=2015-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15778, encodeId=9e8115e786d, content=以阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:03:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312905, encodeId=6d231312905ed, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Thu Feb 12 07:13:00 CST 2015, time=2015-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15329, encodeId=9a8e1532974, content=Profilin1 主要调节invadopodium成熟,与乳腺癌侵犯有关, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=114.90.43.**, createdTime=Tue Feb 10 19:28:00 CST 2015, time=2015-02-10, status=1, ipAttribution=)]
    2015-02-10 114.90.43.**

    Profilin1 主要调节invadopodium成熟,与乳腺癌侵犯有关

    0

相关资讯

乳腺钼靶X线检查不降低乳腺癌死亡率

加拿大的长期研究证实乳腺钼靶X线检查会导致过度诊断并对患者死亡率没有益处——基于此,我们该走向何处? 从20世纪60年代至20世纪80年代所进行的随机试验表明,乳腺钼靶X线检查可降低乳腺癌">乳腺癌的死亡率 (Cochrane Database Syst Rev 2013; 6:CD001877),但这些研究都是在乳腺癌治疗效果较差和女性对乳腺癌的认识程度不高的一个时期内进行的。 目前,

JCO:拉帕替尼+希罗达VS赫赛汀+希罗达用于Her-2阳性转移性乳腺癌

目的:CEREBEL试验对比了Her-2阳性患者在接受“拉帕替尼+希罗达”治疗或接受“赫赛汀+希罗达”治疗后出现疾病复发且以中枢神经系统转移为最先表现的发生率。 材料和方法:无中枢神经系统转移的乳腺癌患者按1:1的比例,随机分为“拉帕替尼+希罗达”组和“赫赛汀+希罗达”组。前者每天服用1250mg拉帕替尼+每21天的1至14天口服希罗达2000mg/m2;后者赫赛汀首次剂量为8mg/kg,之后是

微波热声医疗平台可检测早期乳腺癌

近日,由中国科学院沈阳自动化研究所雷达系统研究与应用技术重点实验室研究开发的用于乳腺肿瘤早期检测的微波热声医疗平台取得新进展。 临床实践证明,早期发现的乳腺癌">乳腺癌(肿瘤直径<2cm)治愈率高达98%以上,因此发现一个早期乳腺癌对患者的意义远大于目前任何治疗方案。 乳腺肿瘤早期检测微波热声医疗平台克服了常规检测方法低分辨率、低对比度、存在电离辐射等问题,利用不同生物组织在微波激

NEJM:未绝经乳腺癌患者的内分泌治疗

对于绝经前早期乳癌女性患者,若病灶免疫组化结果提示雌激素受体阳性或孕激素受体阳性,临床上通常会行内分泌治疗——使用药物抑制卵巢功能,减少雌激素生产,从而减少乳癌复发,但是目前对于该类患者使用添加了他莫昔芬的抑制卵巢雌激素生成疗法的疗效并不明确。因此Prudence A等人进行了一项试验,以评估对进行了完整化疗后未绝经患者以及单独使用他莫昔芬的未绝经患者,行辅助内分泌治疗是否合适。研究的初始数据分析

JCO:早期乳腺癌化疗或增加白血病患病风险

美国研究报道称,早期乳腺癌行预防性化疗或辅助化疗后,罹患白血病的风险将增加,这也意味着额外的治疗并不一定能带来额外的生存获益。他们发现行辅助化疗或预防性化疗的早期乳腺癌患者 10 年罹患白血病累积风险为 0.5%,大约为之前研究报告的 2 倍。该报告的研究者是来自约翰霍普金斯大学医学院肿瘤学的荣誉教授 Judith Karp 博士,他在一份通讯稿中说,骨髓肿瘤如白血病的发病率低,这是毫无疑问的

JCO:更加精准的新乳腺癌风险预测模型

一种新的乳腺癌风险预测模型相比于目前筛选标准能更准确地对乳腺癌风险进行分类,这个模型结合了乳腺组织良性乳腺疾病检查和病人的个体统计信息。梅奥诊所对比新模型和目前的标准——乳腺癌的风险评估工具(bcrat),其结果发表在临床肿瘤学杂志上。 医生进行常规活检来评测乳腺癌的研究结果,可以在乳腺上看到或检查到,即为乳腺癌的存在,“梅奥诊所的外科医生和该研究的资深作者医学博士Amy Degnim说,”然而